Overview
Study information
| Network: | HVTN |
| Grant Affiliation: | NA |
| Strategy: | NA |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | Follow-up (closed to accrual) |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
A Phase I clinical trial to evaluate the safety and immunogenicity of CH505 Envs adjuvanted with GLA-SE, administered alone or with DNA mosaic Env, in healthy, HIV-uninfected adult participants
Description
HVTN 115 is a Phase I clinical trial to evaluate the safety and immunogenicity of EnvSeq-1 Envs (CH505TF, CH505w53, CH505w78, and CH505w100) adjuvanted with GLA-SE, alone or with DNA Mosaic-Tre env.
Sign in to see full information about this study and to download study data.
Products
Product info coming soon!Integrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.